Molecular Genetic Dissection of Inflammatory Linear Verrucous Epidermal Naevus Leads to Successful Targeted Therapy

Journal of Investigative Dermatology (2021) 141, 2979–2983; doi: 10.1016/j.jid.2021.02.765

TO THE EDITOR

Inflammatory linear verrucous epidermal naevus (ILVEN) is a rare skin condition. Classically, it presents at birth or within the first year of life, frequently progressing during early childhood. Diagnostic criteria are erythematous verrucous hyperkeratosis in a fine and whorled Blaschko-linear pattern, intense pruritus, early age of onset, histological features, and resistance to treatment (Morag and Metzker, 1985). The cause of ILVEN has been unknown; however, a single case of mosaicism in gene GJA1 has recently been reported (Umegaki-Arao et al., 2017). We sought to investigate the genetics of ILVEN with a view to new therapeutic angles.

A total of 15 children with ILVEN and six normal controls (from surgery where excess normal skin was available) were recruited with written informed consent by their parents or guardians and Research Ethics Committee approval from the Great Ormond Street Hospital Research and Development office. The patients’ parents/guardians consented to the publication of the patients’ images. DNA and RNA were extracted from skin biopsies of the affected tissue, DNA was extracted from blood by standard methods and affected skin keratinocytes (KC) were cultured and immortalized where possible (Lenti-HPV-16 E6/E7 Virus). Deep whole-exome sequencing of blood and affected skin was performed on patient samples, and data were analyzed using an optimized bioinformatic pathway for the detection of low-level somatic variants as previously published (Al-Olabi et al., 2018). Pathogenic GJA1 variants were not found in any patient. The clinical and histological features of patients 1 and 2 are shown in Figures 1 and 2a and b and Supplementary Table S1.

Heterozygous missense variants in gene CARD14 were detected in 2 of 15 patients (Figure 2c and d). In both patients, the allelic load was compatible with that of a mosaic variant. In patient 1, the variant was present at 20% in both the blood and DNA extracted directly from a whole punch biopsy of the affected skin (c.356T > A, p. (M119K)); and in patient 2, it was present at 1% from DNA extracted directly from the epidermis of the affected skin and it was undetectable in the blood (4/313 reads in skin, c.277A>G, p.(K93E)). We had intended that whole-exome sequencing of the epidermis in patient 2 might have increased the mutant allele load; however, this was not the case, and the 1% load may have been due to mainly cornified epidermis being sequenced. However, both variants were convincing on whole-exome sequencing raw data, and both were clearly confirmed by Sanger sequencing (Figure 2e and f). The missense variant in patient 1 affects the same codon as one previously published in a non-mosaic state causing pityriasis rubra pilaris (Lwin et al., 2018), supporting its likely pathogenicity in vivo and also supported by in silico predictions (SIFT Tolerated, Polyphen2 Benign, Mutation Taster Disease Causing, PROVEAN Neutral, CONDEL Neutral, combined annotation–dependent depletion score 22.6). The variant in patient 2 is predicted overall likely pathogenic in silico (SIFT Tolerated, Polyphen2 Probably Damaging, Mutation Taster Disease Causing, PROVEAN Neutral, CONDEL Deleterious, combined annotation–dependent depletion score 24.1), and since it was to our knowledge previously unreported, we went on to characterize its functional effects. Cultured patient KCs from patient 2 were used to model the variant in the most biologically similar manner. In addition, the patient 2 variant was modeled in a KC cell line (SVK14) that was transfected (Lipopectamine 2000) with CARD14 wild-type and mutant (c.277A > G) pcDNA3.1-HA constructs (Figure 2o). The culture of KCs from patient 1 unfortunately failed, and it was not deemed ethical to take further biopsies from a child for this purpose only.

Quantitative real-time reverse transcription–PCR showed a significant increase in IL-12A and IL-23A in cultured patient KCs and SVK14 cells transfected with the mutant CARD14 construct compared to identically–handled KCs from grouped normal controls (Figure 2g) and SVK14...
cells transfected with the wild-type CARD14 construct (Figure 2h). This was further validated at the protein level by IL-12/IL-23 p40 ELISA (Invitrogen, Waltham, CA). In addition, WST-1 assay (Sigma-Aldrich, St. Louis, MO) showed a significant increase in proliferation rate in patient KCs and SVK14 cells transfected with the mutant CARD14 construct (Figure 2i and j). A significant increase in NF-kB p65 subunit activity was shown by ELISA in nuclear extracts from SVK14 cells transfected with the mutant CARD14 construct (Figure 2l) but not in patient KC nuclear extracts (Figure 2k) (Abcam, Cambridge, United Kingdom), potentially owing to the less physiological model of overexpression in the cell line model.

Inherited (nonmosaic) heterozygous mutations in CARD14 were recently described as rare causes of psoriasis (Jordan et al., 2012) and pityriasis rubra pilaris (Fuchs-Telemer et al., 2012). Variants affecting certain domains of CARD14 were initially described as leading to the activation of NF-kB in the skin (Fuchs-Telemer et al., 2012). However, differences between wild-type and variant CARD14 effects on NF-kB are modest (Li et al., 2015), and not all pathogenic variants increase the activation of NF-kB (Bertin et al., 2001). This includes some of those located in the CARD domain (amino acid sequences 15–107) (Israel and Mellett, 2018) such as that in patient 2. Treatment of patients with germline CARD14 variants with Ustekinumab has been highly successful (Eytan et al., 2014; Lwin et al., 2018); however, direct measurement of the effect of CARD14 variants on IL-12 and IL-23 expression has not previously been performed (Teng et al., 2015). Our findings suggest that IL-12 and IL-23 could be increased by CARD14 variants in a non–NF-kB–dependent manner.

Patient 1 had been resistant to multiple therapies (cyclosporine, acitretin, oral prednisolone), and she had faltering growth (height and weight below the 0.4th centile by age 3 years; birth weight 50th–75th percentile). With hospital drug and therapeutics committee approval, we started treatment at the age of 6 years with Ustekinumab (0.75 mg/kg/dose at 0 and 1 months and 3 monthly thereafter, as per psoriasis protocol). She has had a dramatic and sustained improvement in her skin, now 20 months into treatment, but has required an increase to 8-weekly dosing to maintain effect between doses. She also exhibited catch-up growth, with height and weight improving from the
Figure 2. Histological features and mosaic genetic variants in **CARD14** ILVEN. (a, c, e) Patient 1 and (b, d, f, g, h, i, k, l, m, n) patient 2. (a, b) Histology demonstrating alternating orthokeratosis (white arrow) and parakeratosis (black arrow) in patient 1, with generalized disruption of cornification in patient 2. Histological variability between ILVEN samples (from clinical diagnosis) was found to be very broad. (c, d) Whole-exome sequencing visualized in the Integrative Genomics Viewer (Broad Institute, Cambridge, MA) shows mosaic **CARD14** missense variants c. 356T > A, p. (M119K) (for patient 1 in e) and c.277A > G, p. (K93E) (for patient 2 in d). (e, f) Sanger sequencing chromatograms confirm the variants. Cultured patient KCs and SVK14 cells transfected with a mutant CARD14 construct express increased IL12 and IL23 at mRNA and protein level, proliferate faster than controls, and show variable activity of NF-kB p65. (g, h) QRT-PCR demonstrating a significant increase in IL-12A and IL-23A in cultured KCs from the affected skin from patient 2 and in SVK14 cells transfected with the mutant CARD14 construct in comparison to control patient KCs (n = 3) and SVK14 cells transfected with the wild-type CARD14 construct, respectively. Mean relative gene expression of five replicates per patient sample and duplicates per SVK14 sample was calculated with SD. (i, j) WST-1 proliferation assay showing a proliferation increase in KCs cultured from patient 2 and in SVK14 cells transfected with the mutant CARD14 construct compared to control patient KCs (n = 3) and SVK14 cells transfected with the wild-type CARD14 construct, respectively, measured at 450 nm after 2 and 4 hours. The KCs were cultured for 8 days before proliferation measurement. The mean absorbance of five replicates is shown with SD. (k) Nuclear extracts from patient 2 KCs do not show a difference in NF-kB p65 activity when compared to control patient KCs (n = 6). (l) Nuclear extracts from SVK14 cells transfected with the mutant CARD14 construct show a significant increase in NF-kB p65 activity when compared with SVK14 cells transfected with the wild-type CARD14 construct. The mean absorbance of triplicates is shown with SD. All P-values were calculated by Students t-test using Prism, version 7.0 (GraphPad Software, San Diego, CA). Asterisks indicate a P-value < 0.05. (o) Immunofluorescent anti-HA staining of SVK14 cells transfected with CARD14 wild-type and mutant pcDNA3.1-HA constructs with Sanger-sequencing validation. Bar = 400 um. HA, hemagglutinin; ILVEN, inflammatory linear verrucous epidermal naevus; KC, keratinocyte; QRT-PCR, quantitative real-time reverse transcriptase–PCR.
M Riachi et al.
Molecular Dissection of ILVEN Leads to Successful Therapy

<0.4th to 2—9th percentile within 3 months (Figure 1d and f) and no adverse effects. Patient 2 is younger and less symptomatic (Figure 1g and j) and has not required treatment.

Historically, there has been debate about the clinical and histopathological similarities of ILVEN to congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome and to psoriasis (Happle, 1991; Ito et al., 1991; Moss and Burn, 1990; Welch et al., 1993). We consider that these debates are likely the result of genetic heterogeneity in ILVEN and that the term ILVEN is a clinical description rather than a single histopathological or genetic entity.

We identify in this study that heterozygous missense variants in CARD14 are a recurrent cause of this phenotype, leading to successful targeted medical therapy in one patient. Indications for treatment should be made on an individual patient basis. Genetic counseling should be considered in ILVEN as in these cases, it could be passed on as pityriasis rubra pilaris or psoriasis. These findings underline the power of molecular genetic characterization of rare diseases alongside clinical and histopathological phenotyping.

Data availability statement
No datasets were generated or analyzed during this study.

ORCIDs
Melissa Riachi: http://orcid.org/0000-0001-27228-1780
Satyamaanasa Polubothu: http://orcid.org/0000-0001-7195-5670
Paulina Stadnik: http://orcid.org/0000-0001-9711-4933
Hughes Connor: http://orcid.org/0000-0001-9456-1324
Sara Barberan Martin: http://orcid.org/0000-0003-0142-4078
Carolyn R. Charman: http://orcid.org/0000-0001-6652-7671
Iek Leng Cheng: http://orcid.org/0000-0003-1010-8085
Karolina Gholam: http://orcid.org/0000-0002-8109-6993
Olumide Ogunbivi: http://orcid.org/0000-0001-5208-5526
David G. Paige: http://orcid.org/0000-0003-3583-020X
Neil J. Sebire: http://orcid.org/0000-0001-5348-9063
Alan Pittman: http://orcid.org/0000-0002-8112-2987
Wei-Li Di: http://orcid.org/0000-0002-4851-1649

Veronica A. Kinsler: http://orcid.org/0000-0001-6256-327X

CONFICT OF INTEREST
The authors state no conflict of interest.

ACKNOWLEDGMENTS
We gratefully acknowledge the participation of patients and families in this study and the research coordination by Jane White. VAK was funded by the Wellcome Trust (award WT104076MA), PS was funded by University College London Technology Fund (award number W1140). SP was funded by the National Institute for Health Research Biomedical Research Centre at the University College London Great Ormond Street Institute of Child Health (award number 17BN22). MR and SBM were funded by the Great Ormond Street Hospital Children’s Charity Livingstone Skin Research Centre. The work was supported by the United Kingdom National Institute for Health Research through the Biomedical Research Centre at Great Ormond St Hospital for Children (NHS National Service Foundation Trust and the University College London Great Ormond Street Institute of Child Health. This research was funded in whole or in part by the Wellcome Trust (WT104076MA). For the purpose of Open Access, the author has applied a Creative Commons by public copyright licence to any Author Accepted Manuscript version arising from this submission.

AUTHOR CONTRIBUTIONS
Conceptualization: VAK; Formal Analysis: VAK, MR, SP, PS; Investigation: SP, PS, MR; Resources: VAK, SP, PS, MR, SBM; CRC, OO, ILC, DGP, NJS, WLD, AP; Visualization: SP, MR, PS; Writing - Original Draft Preparation: VAK, SP, MR; Writing - Review and Editing: MR, SP, CH, SBM, CRC, ILC, KG, OO, DGP, NJS, AP, WLD, VAK

Melissa Riachi1,2,10, Satyamaanasa Polubothu1,2,3,4,5, Paulina Stadnik1,10, Connor Hughes4,2, Sara Barberan Martin1,2, Carolyn R. Charman4, Iek Leng Cheng5, Karolina Gholam1, Olumide Ogunbivi5, David G. Paige2, Neil J. Sebire6, Alan Pittman7, Wei-Li Di8,9 and Veronica A. Kinsler1,2,9

1Department of Genetics and Genomic Medicine, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; 2Department of Infection, Immunity and Inflammation Programme, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; 3Department of Histopathology, Great Ormond Street Hospital for Children, London, United Kingdom; 4Department of Dermatology, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 5Pharmacy, Great Ormond Street Hospital for Children, London, United Kingdom; 6Paediatric Dermatology, Royal London Hospital, London, United Kingdom; 7Bioinformatics, St George’s University of London, London, United Kingdom; 8Bioinformatics, St George’s Hospital, London, United Kingdom; 9Immunobiology Section, Infection, Immunity and Inflammation Programme, University College London Great Ormond Street Institute of Child Health, London, United Kingdom

These authors contributed equally to this work.

*Corresponding author e-mail: veronica.kinsler@crick.ac.uk

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2021.02.765.

REFERENCES
Al-Obli L, Polubothu S, Dowsett K, Andrews KA, Stadnik P, Joseph AP, et al. Mosaic RASMAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest 2018;128:5185.
Bentin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, et al. CARD11 and CARD14 Are Novel Caspase Recruitment Domain (CARD)/membrane-associated guanylate kinase (MAGUK) Family Members that InterAct with BCL10 and Activate NF-kappa B. J Biol Chem 2001;276:11877–82.
Eyton O, Sarig O, Sprecher e, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol 2014;171: 420–2.
Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Noursbeck J, et al. Familial Pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012;91:163–70.
Happle R. Child naevus is not ILVEN. J Med Genet 1991;28:214.
Israel L, Mellett M. Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease. Front Immunol 2018;9:2239.
Ito M, Shimizu N, Fujiwara H, Maruyama T, Tetzuka M. Histopathogenesis of inflammatory linear verrucose epidermal naevus: histochemistry, immunohistochemistry and ultrastructure. Arch Dermatol Res 1991;283:491–9.
Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair KP, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012;90:796–806.
Li Q, Jin Chung H, Ross N, Keller M, Andrews J, Kinsler BA, et al. Analysis of CARD14 polymorphisms in Pityriasis rubra pilaris: activation of NF-kB. J Invest Dermatol 2015;135: 1905–8.
Lwin SM, Hsu CK, Liu L, Huang HY, Lewell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol 2018;178:969–72.
Morag C, Metzker A. Inflammatory linear verrucous epidermal nevus: report of seven new cases and review of the literature. Pediatr Dermatol 1985;3:15–8.
Moss C, Burn J. CHILD + ILVEN = PEN or PEN-CIL. J Med Genet 1990;27:390–1.
Genotype-Phenotype Correlation in Trichilemmal Cysts

TO THE EDITOR

Trichilemmal cysts (TCs) present both in autosomal dominant patterns and sporadic patterns (Friedrich and Wilczak, 2019; Seidenari et al., 2013). Recently, Hörer et al. (2019) and later ourselves (Kolodney et al., 2020) independently demonstrated that the p.Ser460Leu PLCD1 variant (NM_006225.4:c.1379 G > A, rs75495843) was the most common risk allele for TCs. A somatic ser745leu PLCD1 mutation was also present in all familial TCs examined. Surprisingly, a ser745leu somatic mutation was always on the same chromosome as the germline p.Ser460Leu variant, in contradiction to the dogma of Knudson’s two hit hypothesis (Knudson, 1971). In our previous study, only one of 17 patients with familial TCs did not harbor a germline p.Ser460Leu variant. That patient had a rare germline p.Glu455Lys variant, in contradiction to the dogma of Knudson’s two hit hypothesis (Knudson, 1971). In our previous study, only one of 17 patients with familial TCs did not harbor a germline p.Ser460Leu variant. That patient had a rare germline p.Glu455Lys variant, in contradiction to the dogma of Knudson’s two hit hypothesis (Knudson, 1971). In our previous study, only one of 17 patients with familial TCs did not harbor a germline p.Ser460Leu variant. That patient had a rare germline p.Glu455Lys variant, in contradiction to the dogma of Knudson’s two hit hypothesis (Knudson, 1971).

Using the UK Biobank, we conducted an unbiased scan for PLCD1 TC risk alleles and characterized select phenotypes related to TCs (see Supplementary Materials and Methods). UK Biobank received ethical approvals from the North West Multicenter Research Ethics Committee, which covers the UK; the Community Health Index Advisory Group, covering Scotland; the Patient Information Advisory Group for gaining access to invite people to participate; and National Research Ethics Service.

Written informed consent was centrally obtained for all UK Biobank participants. We correlated 200,000 PLCD1 exome sequences with inpatient diagnosis of TC. Of the 1,389 PLCD1 variants, six met the preselected threshold (P < 5 × 10−8) for association with TCs (Table 1). To determine variants independently associated with TCs, we estimated pairwise linkage disequilibrium among these six single nucleotide variants. Four associated single nucleotide variants were in high linkage disequilibrium with decreasing P-values adjacent to PLCD1 p.Ser460Leu. Heat maps (r2 and D2) for pairwise linkage disequilibrium of these single nucleotide variants are presented in Supplementary Figure S1. When PLCD1 p.Ser460Leu subjects were removed from the association analysis, only PLCD1 p.Glu455Lys was independently associated with TCs (P = 9.35 × 10−6). Therefore, this targeted interrogation of the six significant single nucleotide variants revealed two independent risk alleles, p.Ser460Leu (minor allele frequency = 0.030) and p.Glu455Lys (minor allele frequency = 1.305 × 10−4).

We explored penetrance by both TC excision and magnetic resonance imaging (MRI). A greater percentage of p.Glu455Lys participants underwent cyst excision (16 of 66 [24.2%]) compared with p.Ser460Leu (1,027 of 28,604 [3.6%]) and wild type (WT) (3,461 of 459,333 [0.8%]) participants (Supplementary Table S1). More p.Glu455Lys participants underwent multiple TC excisions (68.8%) compared with p.Ser460Leu (11.3%) and WT cysts (8.0%). Participants with p.Glu455Lys underwent excision earlier than both p.Ser460Leu and WT participants (mean ± SD, 48.5 ± 8.8 vs. 52.7 ± 9.6 vs. 54.6 ± 9.8 years, respectively, P < 0.001).

MRI is useful to identify TCs (Adachi et al., 1996; Gossner and Larsen, 2010). TC size and number varied by risk allele status, with the larger and more frequent cysts found in p.Glu455Lys participants followed by p.Ser460Leu participants, with WT participants showing the smallest and fewest cysts (Figure 1). Of p.Glu455Lys participants, 91.7% (n = 12) showed TCs on MRI compared with 24.0% of rs75495843 participants and 3.1% of WT participants (Supplementary Table S2). Among subjects with TCs on MRI, p.Glu455Lys participants had more cysts (mean ± SE, 3.8 ± 0.91) than p.Ser460Leu (2.2 ± 0.26) participants and controls (1.2 ± 0.08). The lone p.Glu455Lys participant without TCs on MRI had physician-diagnosed TCs that were likely excised.

We examined sex differences in TC penetrance as measured by both patient diagnosis and presence of cyst on MRI (Supplementary Table S3). Based on our previous study (Kolodney et al., 2020), we classified participants with either of the two PLCD1 risk variants as familial cyst cases and WT as sporadic cyst cases. Females were more likely to be diagnosed with familial TCs (crude OR, 1.35; 95% confidence interval [CI], 1.19–1.54) and less likely to be diagnosed with sporadic cysts (crude OR, 0.72; 95% CI, 0.68–0.77) than
### Supplementary Table S1. Detailed Clinical Features of Patients 1 and 2

| Clinical Features                             | Patient 1                                           | Patient 2                                           |
|----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Age of onset                                 | 11 mo                                               | 1 y                                                 |
| Lesion type                                  | Blaschko-linear erythematous, hyperkeratotic, pruritic | Blaschko-linear erythematous, hyperkeratotic         |
| Lesion distribution                          | Generalized                                         | Appeared on left thumb at ages 4–6 wk               |
| Lesion extent                                | Facial, truncal, and all limbs                       | Facial, truncal, all limbs                          |
| Unilateral / Bilateral                       | Bilateral                                           | Initially unilateral on the left side but progressed to bilateral |
| Palmoplantar involvement (Y/N) and which type| Diffuse palmoplantar keratoderma                     | Linear palmoplantar keratoderma in continuity with arm lesions |

Abbreviations: N, no; Y, yes.